Watch: Biotech Going Up Against Big Pharma

As co-founder, chairman & chief executive of Ocugen, Shankar Musunuri, is looking to bring eye disease products to the patients that big pharma’s drugs have left out. The Malvern, Penn.-based company has four compounds in its pipeline at various stages of development. It’s most advanced candidate, OCU300, is gearing up for Phase III trials in 2018. It’s second candidate, OCU310, combines brimonidine, a drug usually designed for patients with glaucoma, and a steroid. With some of Ocugen’s products, like it’s OCU100 compound designed to delay the progression of retinitis pigmentosa, there is no other drug currently on the market – so there’s no immediate competition. “The goal is to get something to the market to help patients as soon as possible because they don’t have anything today,”

Follow us on social media for the latest updates in B2B!


How Teach for America Brings Diversity in Education to Houston Schools
August 12, 2022
Teach for America has been a cornerstone in creating more educators for the nation. The nonprofit founded in 1989 operates in more than two dozen regions across the country and introduces commitment Read more
The Tips Restaurants Need to Avoid Scammers and Extortionists
August 12, 2022
If restaurants didn’t already have enough to deal with during this pandemic, scheming scammers have cooked up an elaborate plot to target them with negative reviews. According to CBS News, there’s Read more
US Inflation Forecasts Marked Higher for 2023, Survey Shows
August 12, 2022
(Bloomberg) -- Economists boosted their inflation estimates for each quarter in 2023, a potentially worrying sign for Federal Reserve policymakers trying to keep price expectations anchored. The personal Read more